
Albertsons Companies (ACI) Stock Forecast & Price Target
Albertsons Companies (ACI) Analyst Ratings
Bulls say
Albertsons Companies has demonstrated steady growth, with net sales revenue increasing by 2.08% year-over-year, reaching $81.37 billion for the 12 months ending August 2025. The company's pharmacy segment has seen significant growth, with a 19% year-over-year increase in sales, driven by rising prescription volumes and the demand for GLP-1 treatments, which has effectively offset the impacts of moderating food inflation. Additionally, the strong performance of digital sales, which rose by 21% in Q3 2025, indicates a robust e-commerce strategy and customer engagement, contributing positively to the company's resilient overall performance.
Bears say
Albertsons Companies has exhibited a declining trend in several key financial metrics, contributing to a negative outlook on the stock. Gross margin decreased by 60 basis points to 27%, primarily due to higher costs associated with digital fulfillment and a shift towards lower-margin pharmacy revenues. Additionally, Net Operating Profit After Tax (NOPAT) fell by 3.53% year-over-year, and Economic Profit decreased significantly by 29.28%, indicating ongoing profitability challenges amid strategic investments and unfavorable product mix shifts.
This aggregate rating is based on analysts' research of Albertsons Companies and is not a guaranteed prediction by Public.com or investment advice.
Albertsons Companies (ACI) Analyst Forecast & Price Prediction
Start investing in Albertsons Companies (ACI)
Order type
Buy in
Order amount
Est. shares
0 shares